Jonathan Young - Jan 24, 2025 Form 4 Insider Report for Akero Therapeutics, Inc. (AKRO)

Role
Chief Operating Officer
Signature
/s/ Jonathan Young
Stock symbol
AKRO
Transactions as of
Jan 24, 2025
Transactions value $
$274,059
Form type
4
Date filed
1/27/2025, 06:08 PM
Previous filing
Jan 6, 2025
Next filing
Feb 5, 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AKRO Common Stock Options Exercise $274K +43.1K +19.75% $6.36 261K Jan 24, 2025 Direct
holding AKRO Common Stock 20K Jan 24, 2025 By EA Irrevocable Trust F1
holding AKRO Common Stock 20K Jan 24, 2025 By CM Irrevocable Trust F1
holding AKRO Common Stock 20K Jan 24, 2025 By JL Irrevocable Trust F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AKRO Stock Option (Right to Buy) Options Exercise $0 -43.1K -100% $0.00 0 Jan 23, 2025 Common Stock 43.1K $6.36 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares are held in irrevocable trusts for the benefit of the Reporting Person's children. The Reporting Person's spouse is trustee of the trusts. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
F2 The options are vested and currently exercisable.